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A 48-year-old woman receiving combined ipilimumab plus nivolumab treatment for 
metastatic melanoma in a clinical study (CheckMate 401) was admitted to the Karolinska 
University Hospital with fever, nose-bleeds, easy bruising and fatigue. She had received four 
courses with the combination treatment followed by five courses of nivolumab, the last course 
was given three days prior the admission. Absolute neutrophil count was <0.1 x10
9
/L, platelet 
count <5 x10
9
/L and hemoglobin level 115 g/L (suppl.FigS1). The peripheral blood smear 
showed pancytopenia with only scattered lymphocytes (Fig1A). The bone marrow biopsy and 
aspirate showed aplasia; approximately 10% cellularity with scattered lymphoid and few 
erythroid cells without signs of dysplasia. Granulopoiesis and megakaryocytes were 
completely missing. The majority of lymphoid cells were CD8-positive T-lymphocytes. 
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Focally, stromal edema was noted without signs of fibrosis (Fig1B). Daily treatment with 
prednisone (1 mg/kg), and granulocyte colony-stimulating factor (G-CSF) was initiated. In 
protective isolation, the patient received standard antibacterial, antifungal and antiviral 
treatment and after her second day of admission she had no signs of infections. She received 
antifibrinolytic treatment with tranexamic acid and repeated platelet transfusions. Since there 
were no signs of recovery in her pancytopenia, arrangements were made to initiate aplastic 
anemia treatment with anti-thymocyte globulin (ATG), which also has been used to treat 
ipilimumab-induced hepatitis[1, 2]. However, at the eleventh day of hospitalization she 
suffered a brain hemorrhage with a rapid fatal outcome. Postmortem examination revealed a 
large intracerebral hemorrhage but no signs of brain/leptomeningeal metastases or vascular 
disease, hence the hemorrhage most likely resulted from the persistent thrombocytopenia. 
Microscopic examination of the postmortem bone marrow showed aplasia without 
engagement of melanoma cells (Fig1C). Immunohistochemistry confirmed the predominance 
of CD8-positive T-lymphocytes in the postmortem bone marrow (not shown). Microscopic 
examination of liver metastases showed viable melanoma cells with CD3- and CD8 positive 
lymphoid cell infiltration localized mostly at the periphery of the lesions (Fig1D and 
suppl.FigS2). 
Immune checkpoint blockade with PD-1 and CTLA-4 inhibitors have proven effective in the 
treatment of metastatic melanoma and also of several other tumors[3]. Combination therapy 
with PD-1 inhibitor nivolumab and CTLA-4 inhibitor ipilimumab further improves 
progression-free survival in patients with metastatic melanoma, however the combination 
therapy increases the risk of immune-related adverse events, in particular diarrhea/colitis, 
hepatitis, pruritus/rash and endocrine dysfunction[4]. To the authors’ knowledge, this is the 
first reported case of aplastic anemia with a lethal outcome, induced by ipilimumab and 
nivolumab combination therapy. In the summary of product characteristics 
(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/003985/WC500189765.pdf), grade 3-4 anemia, neutropenia 
and thrombocytopenia were reported in 2.8%, 0.7% and 1.2% of patients treated with 
nivolumab plus ipilimumab (n=448). Furthermore, there have been reports of cases with 
checkpoint blockade induced cytopenias [4, 5]. Collectively, this indicates that in a small 
proportion of patients receiving these treatments, bone marrow suppression occurs, in some 
cases probably resulting from T-cell activation against early hematopoietic progenitors. Our 
case illustrates the importance of detecting low peripheral blood counts timely in patients on 
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checkpoint blockade treatments, and if necessary withhold treatment and initiate a 
multidisciplinary approach to diagnose and treat this complication. 
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Figure 1. May-Grünwald-Giemsa-stained peripheral blood smear (40x magnification) 
showing pancytopenia with only scattered lymphocytes present (A). Immunohistochemical 
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stain for CD8 of the premortem bone marrow biopsy (20x magnification) with the majority of 
lymphoid cells CD8-positive (B). Hematoxylin and eosin stained section of the postmortem 
bone marrow (20x magnification) showing hypoplasia with scattered lymphoid and few 
erythroid cells without signs of dysplasia and granulopoiesis and megakaryocytes completely 
missing (C). Hematoxylin and eosin stained liver metastasis (20x magnification) showing 
viable melanoma cells with lymphocytes at the periphery of the lesions (A). 
 
 
 
 
Supplementary Figure S1. The patient’s peripheral blood cell counts and courses of 
treatment displayed in a timeline chart. The lower range of blood values are indicated by red 
asterisks on the y-axes. 
 
 
 
 
 
 
Supplementary Figure S2. Hematoxylin and eosin stained liver metastasis (20x 
magnification) showing viable melanoma cells with lymphocytes at the periphery of the 
lesion (A). Same section of liver metastasis as in (A) with immunohistochemical stain for 
CD3, showing CD3 positive lymphoid cells infiltrating the periphery of the metastatic lesion 
(B). 
  
 
 
May-Grünwald-Giemsa-stained peripheral blood smear (40x magnification) showing pancytopenia with only 
scattered lymphocytes present (A). Immunohistochemical stain for CD8 of the premortem bone marrow 
biopsy (20x magnification) with the majority of lymphoid cells CD8-positive (B). Hematoxylin and eosin 
stained section of the postmortem bone marrow (20x magnification) showing hypoplasia with scattered 
lymphoid and few erythroid cells without signs of dysplasia and granulopoiesis and megakaryocytes 
completely missing (C). Hematoxylin and eosin stained liver metastasis (20x magnification) showing viable 
melanoma cells with lymphocytes at the periphery of the lesions (A).  
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